SOMMAIRE
1. AML and Oncomine Myeloid Assay GX V2 2 years long CHU Nîmes experience : How it …
2. Disclaimer
3. ---
4. Biomarker analysis drives improvements in AML patient outcomes
5. Myeloid Neoplasms
6. AML is a genetically heterogenous disease​
7. WHO: acute myeloid leukemia classification
8. ELN 2022 guidelines and International consensus classification (ICC) …
9. Treatment decisions are based on Risk stratification
10. Molecular testing across the care continuum
11. Treatment decisions are based on Risk stratification
AML and Oncomine Myeloid Assay GX V2
2 years long CHU Nîmes experience :
How it can improve our efficiency? 
Dr S CARILLO, CHU Nîmes
00000000000000000000000000000000